| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 4A3702A96F |
| InChI Key | XHCSBQBBGNQINS-DOTOQJQBSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C24H29Cl2NO3 |
| Molecular Weight | 450.41 |
| AlogP | 4.75 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 6.0 |
| Polar Surface Area | 60.77 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 30.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| POSITIVE ALLOSTERIC MODULATOR | Dopamine D1 receptor positive allosteric modulator | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Monoamine receptor
Dopamine receptor
|
1-13 | - | - | - | - | |
|
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Monoamine receptor
Serotonin receptor
|
- | 3800 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Lewy Body Disease | 2 | D020961 | ClinicalTrials |
| Parkinson Disease | 1 | D010300 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL3421729 |
| FDA SRS | 4A3702A96F |
| Guide to Pharmacology | 10506 |
| PDB | G4C |
| PubChem | 86290953 |
| SureChEMBL | SCHEMBL16267372 |
| ZINC | ZINC000220050656 |